A Pipeline that Breaks Barriers
Vertero is building a focused pipeline of novel small molecule therapeutics for peripheral drivers of neurogenerative diseases, aiming to bring new hope to affected communities.
| ASSET | INDICATION | DISCOVERY | PRECLINICAL | IND-ENABLING | PHASE I | PHASE II |
| VT-5006 CsgA inhibitor |
Parkinson’s Disease | |||||
| VT-6382 Bile salt hydrolase inhibitor |
Undisclosed | |||||
VT-5006
Vertero’s lead candidate, VT-5006, is a first-in-class, gut-selective small molecule designed to slow disease onset and progression and preserve quality of life for people with Parkinson’s disease (PD).
The molecule acts on CsgA, a microbial amyloid used by bacteria to anchor to the GI wall and drives the aggregation of alpha-synuclein (⍺Syn) and inflammation that propagates to the brain and provokes PD.
By targeting CsgA, VT-5006 aims to reduce the load of aggregation and dampen the associated inflammation — potentially both alleviating symptoms and slowing disease progression to preserve quality of life as long as possible.
In preclinical research, VT-5006 reduced brain pathology, reduced inflammation in the brain, improved motor function, and slowed disease progression with a favorable safety profile. Vertero is now preparing to initiate its first clinical study of VT-5006.